VivoSeq
Oncology

Metastatic Soft-Tissue Sarcoma

3

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Metastatic Soft-tissue Sarcoma is an early-stage landscape with 3 programs across 3 companies. The most active players are Bristol-Myers Squibb, Merck & Co., Alaunos Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1A

Alaunos Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Zanzalintinib

Merck & Co.

Ipilimumab

Bristol-Myers Squibb

Nivolumab

Bristol-Myers Squibb

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

7

clinical trials

Active, not recruiting2 · 29%
Not yet recruiting2 · 29%
Withdrawn1 · 14%
Unknown status1 · 14%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Recruiting·WWashington University School of Medicine·Phase 1·NCT06968988·18 enrolled
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
Active, not recruiting·IInstitut Bergonié·Phase 2·NCT04095208·67 enrolled
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Active, not recruiting·—·Phase 2·NCT04733183·98 enrolled
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07283731·20 enrolled
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA
Not yet recruiting·MMedSIR·Phase 1/2·NCT07460986·278 enrolled
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Withdrawn·PPeking University People's Hospital·Phase 2/3·NCT03342300
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Unknown status·AAlaunos Therapeutics·Phase 2·NCT00718484·67 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)